Bone loss and fracture risk associated with cancer therapy

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Background. Cancer patients experience osteoporosis resulting from accelerated loss of bone mineral density (BMD) caused by their treatment. Such bone loss greatly increases the risk for fracture and can have other serious effects on quality of life. Methods. In the current report, the author focuses on studies of cancer therapy-associated bone loss, its prevalence and pathogenesis, and resulting clinical impact. Options for management and prevention are also reviewed, including treatment guidelines where available. Results. A variety of cancer therapies, including hormonal therapy, chemotherapy, and glucocorticoids, affect gonadal hormone production, which increases bone resorption and decreases BMD. Such bone loss occurs more rapidly and to a greater degree than normal age-related osteoporosis, increases the risk for fracture and other morbidities, and decreases survival. Regular BMD screening and early intervention can prevent further decline in bone density and bone quality. Pharmacologic therapy with oral and i.v. bisphosphonates has been shown to slow bone loss in patients receiving cancer therapy, and the i.v. bisphosphonate zoledronic acid can increase BMD in patients with cancer treatment-related bone loss. Lifestyle changes, including supplementation with calcium and vitamin D, diet, and proper exercise, can also slow the rate of bone loss. Conclusions. Bone loss associated with various cancer therapies significantly affects bone health. Early initiation of bisphosphonates, when indicated, and lifestyle modification can improve patient outcomes. Education of patients and health care professionals regarding the importance of this complication and effective treatment options is essential.

Original languageEnglish (US)
Pages (from-to)1121-1131
Number of pages11
JournalOncologist
Volume11
Issue number10
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Second Primary Neoplasms
Bone Fractures
Bone and Bones
Bone Density
Diphosphonates
zoledronic acid
Therapeutics
Osteoporosis
Life Style
Neoplasms
Gonadal Hormones
Patient Education
Bone Resorption
Vitamin D
Glucocorticoids
Patient Care
Quality of Life
Guidelines
Exercise
Diet

Keywords

  • Bisphosphonates
  • Cancer
  • Chemotherapy
  • Fracture
  • Hormonal antineoplastic agents
  • Osteoporosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Bone loss and fracture risk associated with cancer therapy. / Guise, Theresa.

In: Oncologist, Vol. 11, No. 10, 11.2006, p. 1121-1131.

Research output: Contribution to journalArticle

@article{59481559e0844a689538928a4d133fc2,
title = "Bone loss and fracture risk associated with cancer therapy",
abstract = "Background. Cancer patients experience osteoporosis resulting from accelerated loss of bone mineral density (BMD) caused by their treatment. Such bone loss greatly increases the risk for fracture and can have other serious effects on quality of life. Methods. In the current report, the author focuses on studies of cancer therapy-associated bone loss, its prevalence and pathogenesis, and resulting clinical impact. Options for management and prevention are also reviewed, including treatment guidelines where available. Results. A variety of cancer therapies, including hormonal therapy, chemotherapy, and glucocorticoids, affect gonadal hormone production, which increases bone resorption and decreases BMD. Such bone loss occurs more rapidly and to a greater degree than normal age-related osteoporosis, increases the risk for fracture and other morbidities, and decreases survival. Regular BMD screening and early intervention can prevent further decline in bone density and bone quality. Pharmacologic therapy with oral and i.v. bisphosphonates has been shown to slow bone loss in patients receiving cancer therapy, and the i.v. bisphosphonate zoledronic acid can increase BMD in patients with cancer treatment-related bone loss. Lifestyle changes, including supplementation with calcium and vitamin D, diet, and proper exercise, can also slow the rate of bone loss. Conclusions. Bone loss associated with various cancer therapies significantly affects bone health. Early initiation of bisphosphonates, when indicated, and lifestyle modification can improve patient outcomes. Education of patients and health care professionals regarding the importance of this complication and effective treatment options is essential.",
keywords = "Bisphosphonates, Cancer, Chemotherapy, Fracture, Hormonal antineoplastic agents, Osteoporosis",
author = "Theresa Guise",
year = "2006",
month = "11",
doi = "10.1634/theoncologist.11-10-1121",
language = "English (US)",
volume = "11",
pages = "1121--1131",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Bone loss and fracture risk associated with cancer therapy

AU - Guise, Theresa

PY - 2006/11

Y1 - 2006/11

N2 - Background. Cancer patients experience osteoporosis resulting from accelerated loss of bone mineral density (BMD) caused by their treatment. Such bone loss greatly increases the risk for fracture and can have other serious effects on quality of life. Methods. In the current report, the author focuses on studies of cancer therapy-associated bone loss, its prevalence and pathogenesis, and resulting clinical impact. Options for management and prevention are also reviewed, including treatment guidelines where available. Results. A variety of cancer therapies, including hormonal therapy, chemotherapy, and glucocorticoids, affect gonadal hormone production, which increases bone resorption and decreases BMD. Such bone loss occurs more rapidly and to a greater degree than normal age-related osteoporosis, increases the risk for fracture and other morbidities, and decreases survival. Regular BMD screening and early intervention can prevent further decline in bone density and bone quality. Pharmacologic therapy with oral and i.v. bisphosphonates has been shown to slow bone loss in patients receiving cancer therapy, and the i.v. bisphosphonate zoledronic acid can increase BMD in patients with cancer treatment-related bone loss. Lifestyle changes, including supplementation with calcium and vitamin D, diet, and proper exercise, can also slow the rate of bone loss. Conclusions. Bone loss associated with various cancer therapies significantly affects bone health. Early initiation of bisphosphonates, when indicated, and lifestyle modification can improve patient outcomes. Education of patients and health care professionals regarding the importance of this complication and effective treatment options is essential.

AB - Background. Cancer patients experience osteoporosis resulting from accelerated loss of bone mineral density (BMD) caused by their treatment. Such bone loss greatly increases the risk for fracture and can have other serious effects on quality of life. Methods. In the current report, the author focuses on studies of cancer therapy-associated bone loss, its prevalence and pathogenesis, and resulting clinical impact. Options for management and prevention are also reviewed, including treatment guidelines where available. Results. A variety of cancer therapies, including hormonal therapy, chemotherapy, and glucocorticoids, affect gonadal hormone production, which increases bone resorption and decreases BMD. Such bone loss occurs more rapidly and to a greater degree than normal age-related osteoporosis, increases the risk for fracture and other morbidities, and decreases survival. Regular BMD screening and early intervention can prevent further decline in bone density and bone quality. Pharmacologic therapy with oral and i.v. bisphosphonates has been shown to slow bone loss in patients receiving cancer therapy, and the i.v. bisphosphonate zoledronic acid can increase BMD in patients with cancer treatment-related bone loss. Lifestyle changes, including supplementation with calcium and vitamin D, diet, and proper exercise, can also slow the rate of bone loss. Conclusions. Bone loss associated with various cancer therapies significantly affects bone health. Early initiation of bisphosphonates, when indicated, and lifestyle modification can improve patient outcomes. Education of patients and health care professionals regarding the importance of this complication and effective treatment options is essential.

KW - Bisphosphonates

KW - Cancer

KW - Chemotherapy

KW - Fracture

KW - Hormonal antineoplastic agents

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=33751203850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751203850&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.11-10-1121

DO - 10.1634/theoncologist.11-10-1121

M3 - Article

C2 - 17110632

AN - SCOPUS:33751203850

VL - 11

SP - 1121

EP - 1131

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -